Main description:

This book discusses the latest developments in Poly (ADP-ribose) polymerase (PARP) inhibitor drug development. It focuses on the translational and clinical development of the latest drugs, as well as the evidence for regulatory approval of PARP inhibitors in multiple different molecular subtypes and tumor indications. The most-up-to-date information on basic scientific research on DNA repair pathways and the DNA Damage Response (DDR) is also covered. Every chapter contains insight into the preclinical, translational along with clinical aspects of a specific DDR inhibitor with key and expert opinion points reinforcing the most important concepts detailed to enable the reader to develop a deep understanding of the topic.
Targeting the DNA Damage Response for Cancer Therapy comprehensively reviews the application of PARP and other DDR inhibitors across oncology disciplines. Therefore, it is a valuable resource for all medical professionals and researchers who use or who are researching the use of these inhibitors on a day-to-day basis.

Contents:

Overview of DNA repair pathways and DNA damage response.- Exploiting Synthetic Lethality through PARP inhibition in BRCA mutated cancers.- Expanding the role of PARP inhibitor monotherapy beyond BRCA mutated cancers.- PARP trapping and implications for the clinical application of PARP inhibitors.- Resistance mechanisms associated with PARP inhibitors.- Identification of genetic predictive biomarkers of response.- Development of homologous recombination functional assays for PARP inhibitors.- Clinical application of PARP inhibitors in ovarian cancer.- Clinical use of PARP inhibitors in BRCA mutant and non-BRCA mutant breast cancer.- Development of PARP inhibitors in targeting castration-resistant prostate cancer.- Management of patients with BRCA and non-BRCA mutated pancreatic cancer with PARP inhibitors.- Radiosensitization of PARP inhibitors and implications for the Clinic.- Combining PARP inhibitors with chemotherapeutic agents: progress, pitfalls and promises.- Rational combination of PARP inhibitors with antiangiogenic agents in BRCA and non-BRCA mutated cancers.- Rational combination of PARP inhibitors with molecularly targeted agents through the induction of chemical BRCAness.- Combinations of PARP inhibitors with other DNA damage response (DDR) inhibitors.-Combining PARP inhibitors with immunotherapy.- Moving beyond PARP inhibitors in Cancer Therapy; What next?.